ADAR1 (E1008Q) FLAG-tag Recombinant

• Background:

  ADAR1 (adenosine deaminase, RNA-specific 1) performs adenosine to inosine base editing in RNA, particularly targeting adenosines located within a specific stem-loop motif structure. It is proposed that ADARs evolved to provide additional diversity to the transcriptome and while the majority of ADAR editing events occur in non-coding RNAs, some, including the canonical GluA2 editing site, alter the amino acid sequence of coding proteins. ADAR1 plays a role in innate immunity by mitigating interferon signaling. Dysfunction of ADAR1 results in autoimmune disorders, and impacts cancer cell growth and proliferation as well as tumor response to immunotherapy. Since ADAR recognizes double-stranded RNA, it also functions to suppress or modify RNA viruses. Thus, it is implicated in viral evolution and in the emergence of viral variants such as SARS-CoV-2 variants. The E1008Q mutant of ADAR1 has been proposed to demonstrate higher editing activity than its wild type, with the mutation being present in a highly conserved glutamate present in the deaminase domain of the protein.

• Description:

  Recombinant human full-length ADAR1 (adenosine deaminase, RNA-specific 1) transcript 1, encompassing amino acids 2-1226 (end) . This protein contains the mutation of interest E1008Q. This construct contains an N-terminal FLAG-tag. The recombinant protein was affinity purified.

• UniProt:

  P55265

• Applications:

  Useful for the study of binding of ADAR1 and RNA and screening inhibitors of this interaction.

• Purity:

  ≥ 80%

• Format:

  Aqueous buffer solution

• Shipping Conditions:

  -80°C

• Storage Conditions:

  > 6 months at –80°C.

• Calculated Molecular Weight:

  137 kDa

• Formulation:

  50 mM Tris-HCl, pH 8.0,750 mM NaCl, 0.01% Triton X-100,10% glycerol and 100 μg/ml FLAG peptide.